Matthew Manning Riggs

Title: Matthew Manning Riggs: Innovator in Osteogenesis Imperfecta Treatment

Introduction

Matthew Manning Riggs is a notable inventor based in Haddam, Connecticut. He has made significant contributions to the field of medical treatments, particularly in addressing osteogenesis imperfecta, a genetic disorder characterized by fragile bones.

Latest Patents

Riggs holds a patent for the "Use of anti-sclerostin antibodies in the treatment of osteogenesis imperfecta." This patent discloses methods for treating patients suffering from this condition by administering a therapeutically effective amount of an anti-sclerostin antibody. The invention outlines methods for increasing bone formation and reducing bone resorption in osteogenesis imperfecta patients. Additionally, it provides compositions that comprise a therapeutically effective amount of an anti-sclerostin antibody for the same purpose.

Career Highlights

Matthew Manning Riggs is associated with Mereo Biopharma 3 Limited, where he continues to work on innovative solutions for bone-related disorders. His research and development efforts focus on improving the quality of life for patients affected by osteogenesis imperfecta.

Collaborations

Riggs collaborates with esteemed colleagues such as Uwe Junker and Michaela Kneissel, contributing to a team dedicated to advancing medical treatments.

Conclusion

Matthew Manning Riggs is a pioneering inventor whose work in the treatment of osteogenesis imperfecta showcases the potential of anti-sclerostin antibodies. His contributions are vital in the ongoing quest to enhance patient care and treatment outcomes.